土耳其烟草使用障碍患者 APC2、NR3C1 和 DRD2 基因启动子的甲基化。

Methylation of APC2, NR3C1, and DRD2 gene promoters in turkish patients with tobacco use disorder.

机构信息

Department of Chest Disease, University of Health Sciences, Yedikule Training and Research Hospital of Chest Diseases and Thoracic Surgery, Istanbul.

Department of Chest Disease, University of Health Sciences, Yedikule Training and Research Hospital of Chest Diseases and Thoracic Surgery, Istanbul, Turkey.

出版信息

Niger J Clin Pract. 2022 Feb;25(2):160-166. doi: 10.4103/njcp.njcp_25_21.

DOI:10.4103/njcp.njcp_25_21

PMID:35170441

Abstract

BACKGROUND

Many studies have investigated the association of the methylation of gene and tobacco use disorders (TUD), but results remain ambiguous.

AIMS

This study evaluated the relationship between methylation of Adenomatosis Polyposis Coli (APC), Nuclear Receptor subfamily 3 group C member 1 (NR3C1), Dopamine D2 receptor (DRD2) gene promoters, and its effect on TUD.

SUBJECTS AND METHODS

We recruited 154 active smokers and 111 healthy non-smoker controls. PCR based methods on genomic DNA characterized the methylation of APC2, NR3C1, and DRD2 gene promoters.

RESULTS

We have found a significant difference in methylation of APC2 for TUD compared to healthy controls (P < 0.001). The partial methylation ratio was about an eight-fold increase in smokers compared to healthy controls. NR3C1 methylation was slightly higher in TUD patients compared to the control group, but the difference was not significant between the two groups (%95.33 vs. 91.08, P = 0.269). DRD2 methylation ratio was not significant between TUD patients and healthy control groups (P = 0.894).

CONCLUSION

We think that it is important to detect APC2 methylated cases earlier and to advise them to quit smoking.

摘要

背景

许多研究已经调查了基因甲基化与烟草使用障碍（TUD）之间的关联，但结果仍存在分歧。

目的

本研究评估了腺瘤性结肠息肉病（APC）、核受体亚家族 3 组 C 成员 1（NR3C1）和多巴胺 D2 受体（DRD2）基因启动子甲基化与 TUD 之间的关系。

受试者和方法

我们招募了 154 名主动吸烟者和 111 名健康非吸烟者作为对照。基于聚合酶链反应（PCR）的方法对基因组 DNA 进行分析，以确定 APC2、NR3C1 和 DRD2 基因启动子的甲基化情况。

结果

我们发现 TUD 患者 APC2 的甲基化与健康对照组相比存在显著差异（P<0.001）。与健康对照组相比，吸烟者的 APC2 部分甲基化比例增加了约 8 倍。与对照组相比，TUD 患者的 NR3C1 甲基化水平略高，但两组之间的差异无统计学意义（%95.33 与 91.08，P=0.269）。DRD2 甲基化比例在 TUD 患者和健康对照组之间无显著差异（P=0.894）。